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Introduction
Hypertension is one of the most important modiﬁ-
able causes of premature death worldwide, and is
estimated to cause 7.1 million premature deaths.
Approximately one billion people worldwide have
hypertension and the prevalence is predicted to
increase dramatically in the next few years (1,2).
Hypertension is a major risk factor for both cardio-
vascular (CV) and cerebrovascular morbidity and
mortality (1), contributing to approximately 50% of
all CV events (3). The relationship between blood
pressure (BP) and CV risk is continuous – for every
20 mmHg increase in systolic blood pressure (SBP) or
10 mmHg increase in diastolic blood pressure (DBP),
the risk of cardiovascular disease (CVD) doubles (4).
Patients with hypertension are also more likely to
have associated CV risk factors (5); for example,
approximately 50% of patients with hypertension
have hypercholesterolaemia and 20–40% have hyper-
glycaemia. The presence of multiple risk factors
increases the risk of CV events associated with hyper-
tension. The most common risk factors for CVD
include advanced age (> 55 years for men and
> 65 years for women), smoking, dyslipidaemia,
family history of premature CVD, abdominal obesity,
abnormal C-reactive protein levels and clinical condi-
tions such as diabetes and renal disease (6). As a
result, current treatment guidelines emphasise the
importance of risk stratiﬁcation to determine BP tar-
gets and appropriate antihypertensive treatment regi-
mens (6). For example, in patients with diabetes or
other additional risk factors, the BP targets are lower:
SBP < 130 mmHg and DBP < 80 mmHg, vs. SBP
< 140 mmHg and DBP < 90 mmHg in patients with
no additional risk factors (2,6,7).
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SUMMARY
The increasing prevalence of hypertension, owing to modern lifestyles and the
increasing elderly population, is contributing to the global burden of cardiovascular
(CV) disease. Although effective antihypertensive therapies are available, blood
pressure (BP) is generally poorly controlled. In addition, the full beneﬁts of antihy-
pertensive therapy can only be realised when target BP is achieved. International
guidelines and clinical trial evidence support the use of combination therapy to
manage hypertension. In high-risk patients, such as those with coronary artery dis-
ease, diabetes and renal dysfunction, BP targets are lower and there is a need for
intensive management with combination therapy to control BP and provide addi-
tional CV risk reduction beneﬁts. Combinations of antihypertensive agents with dif-
ferent but complementary modes of action improve BP control and may also
provide vascular-protective effects. Calcium channel blockers (CCBs) have been
shown to be effective in combination with a range of antihypertensive drugs and
in different patient populations. As part of a ﬁrst-line combination strategy, CCBs
can provide CV beneﬁts beyond BP control, even in patients at increased CV risk.
Beneﬁts include protection against end-organ damage and serious CV events.
Indeed, in major intervention trials, these beneﬁts have already been clearly dem-
onstrated. Ongoing studies will provide further data to support the clinical beneﬁts
of combination therapy as a ﬁrst-line treatment approach. Implementation of this
approach in clinical practice, together with adherence to global hypertension man-
agement guidelines will help ensure patients achieve and sustain BP targets, and
reduce the risk of CV events.
Review Criteria
A literature search was conducted to identify recent
randomised studies assessing CCB-based
combination therapy strategies.
Message for the Clinic
Despite guideline recommendations, combination
therapy is an underused strategy for the treatment
of hypertension. Calcium channel blocker (CCB)-
based combination strategies are effective and well
tolerated when used with other classes of
antihypertensive drugs, and should be considered a
ﬁrst-line option in hypertensive patients, particularly
in those at high cardiovascular risk.
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to reduce CV morbidity and mortality by preventing
end-organ damage (6–8). Numerous intervention
studies have shown that BP control is associated with
signiﬁcant reductions in CV morbidity and mortality.
Even modest reductions in SBP or DBP for short
periods of time substantially improve CV outcomes,
particularly in high-risk patients (9). For example,
antihypertensive therapy is associated with a 35–40%
reduction in stroke, a 20–25% reduction in myocar-
dial infarction, a > 50% reduction in heart failure
and reductions in CVD-related death rates (6,10). In
addition to appropriate management of additional
risk factors and associated clinical conditions, early,
intensive and effective BP control is required in the
prevention and management of CVD (6,8).
Blood pressure control and
achievement of guideline goals
Although effective therapies exist, current BP control
is still below the ‘Healthy People 2010’ goal of 50%:
only 34% of patients with hypertension have ade-
quately controlled BP, 59% have treated but uncon-
trolled BP and 30% are unaware of their condition
(7). Poorly controlled BP, particularly SBP, is associ-
ated with increased CV morbidity and mortality, and
end-organ damage (11). Despite the availability of
effective antihypertensive treatments, adequate BP
control is often not achieved, highlighting the need
for greater efforts in the management of hyperten-
sion.
Hypertension guidelines have traditionally recom-
mended stepwise regimens to lower BP in patients
with hypertension, beginning with lifestyle modiﬁca-
tion (e.g. weight reduction, increased physical activ-
ity, dietary changes, smoking cessation and
moderation of alcohol consumption), and adding
pharmacological intervention when lifestyle changes
are insufﬁcient (2,6,7,12). Immediate initiation of
antihypertensive therapy, together with lifestyle
changes is recommended in individuals at high or
very high risk; whereas, for those at low or moderate
risk, the effects of lifestyle changes should be moni-
tored for several weeks before initiation of antihyper-
tensive treatment (6). Guidelines also recommend
that antihypertensive therapy should be started grad-
ually to achieve target BP values progressively over
several weeks.
Data from outcome studies show that several clas-
ses of drugs, including angiotensin-converting
enzyme (ACE) inhibitors, angiotensin-receptor
blockers (ARBs), beta-blockers, calcium channel
blockers (CCBs) and thiazide-type diuretics, effec-
tively lower BP and reduce the complications of
hypertension (10,13–16). However, the recent
ESH⁄ESC guidelines recommend that the presence of
additional conditions, such as diabetes or coronary
artery disease (CAD), or possible contraindications
should be considered when selecting the initial anti-
hypertensive agent (6).
In clinical practice, hypertension management var-
ies greatly and many factors contribute to inadequate
BP control, the most important include: patient non-
compliance; acceptance of inadequate BP control by
clinicians and reluctance to titrate the dose, switch to
another drug or add another drug; and the fact that
it is difﬁcult to achieve adequate BP control with
monotherapy in most patients, even when the dose
is optimised (17). Response rates with any class of
antihypertensive administered as monotherapy range
from 30% to 60%; however, no monotherapy has
been shown to achieve target BP in more than 20–
30% of the overall hypertensive population (18,19).
By contrast, combining two complementary antihy-
pertensive agents has been shown to improve the
response rate to 75–90% (17), and the results of the
Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT) showed that about nine of 10 patients
required two or more antihypertensive agents to
reduce BP to < 140⁄90 mmHg (20). Therefore, most
patients, particularly those at high CV risk, will
require combination therapy with two or more anti-
hypertensive medications to achieve controlled BP,
and recent guidelines recommend that two-drug
combination therapy be considered a ﬁrst-line alter-
native to monotherapy (2,6,7).
Compared with high-dose monotherapy, combina-
tion therapy is associated with fewer adverse effects.
Guidelines advocate combination therapy with once
daily treatment regimens that provide 24-h efﬁcacy.
The advantages of combination therapy include
improved adherence to therapy (21) and minimisa-
tion of BP variability. In addition, combining two
antihypertensive agents with different mechanisms of
action may provide greater protection against major
CV events and the development of end-organ dam-
age (6). The challenge remains to translate the evi-
dence and recommendations outlined in the current
hypertension management guidelines into clinical
practice, as combination therapy remains underused,
especially in high-risk patients (22).
Combination therapy – the evidence
Combination therapy was traditionally reserved as a
third- or fourth-line approach in hypertension man-
agement (7); however, several major intervention tri-
als in various high-risk patient populations have
shown that an average of two to four antihyperten-
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trol to target levels (Figure 1) (23–29). A signiﬁcant
level of support for combination therapy is also pro-
vided by monotherapy studies in which additional or
background antihypertensive therapy was required to
effectively lower BP (Table 1) (13,14,16,24–26,30–
35).
Guidelines recommend various two-drug combina-
tions of different classes of antihypertensive agents
based on data derived from controlled interventional
trials, but advise that three or four drugs may be
required depending on the patient’s risk proﬁle.
Although older therapies such as diuretics and beta-
blockers can effectively lower BP and are included as
possible ﬁrst-line combinations, they are associated
with some disadvantages (6). For example, beta-
blockers offer no beneﬁt to elderly patients with
uncomplicated hypertension. Furthermore, they may
be associated with an increased risk of stroke (36)
and impaired glucose and lipid metabolism (37).
These studies recommend that beta-blockers should
not be ﬁrst choice for the treatment of uncompli-
cated hypertension. When diuretics are administered
at higher doses or in combination with beta-blockers,
they are associated with increased risks of new-onset
diabetes (37). Evidence to support the use of diuret-
ics as ﬁrst-line treatment has also been questioned
and these concerns are reﬂected in recent guidelines
(6).
By contrast, many studies have shown that newer
antihypertensive agents, such as CCBs, ARBs and
ACE inhibitors, provide additional beneﬁts by reduc-
ing the incidence of CV events in patients with
hypertension (14,16,25,30). In addition, cases of
new-onset diabetes are less common with newer anti-
hypertensive agents than with older therapies such as
diuretics and beta-blockers (37). Whether this is due
to the deleterious effect of older agents on glucose
metabolism or a positive effect of newer agents
remains to be fully determined.
CCBs in combination therapy –
evidence supporting additional
treatment beneﬁts
Combination studies
Calcium channel blockers are used extensively in
clinical practice and data from several clinical studies
show that CCBs effectively and safely lower BP and
reduce long-term CV risk in a wide range of patient
populations (24,32,35,38,39). It is of note that while
most studies have investigated the efﬁcacy and safety
of dihydropyridine CCBs, there are some studies
supporting the beneﬁts of non-dihydropyridine CCBs
(33,40,41). However, for the purpose of this review,
data presented on CCBs are for dihydropyridine
CCBs.
As CCBs have a different mode of action to com-
monly used inhibitors of the renin–angiotensin–aldo-
sterone (RAAS) pathway (such as ACE inhibitors
and ARBs), combination with these agents should
provide synergistic or complementary effects, com-
pared with using two agents that inhibit the same
pathway. Indeed, in patients with newly diagnosed
stage 1 or 2 hypertension or in patients with inade-
quate BP control after conventional low-dose mono-
therapy, low-dose combination therapy with CCBs
and ARBs was found to provide better BP control
than either high-dose monotherapy (p < 0.05 vs.
either monotherapy) (42). Further evidence for the
Figure 1 Two to four antihypertensive agents are required to achieve effective BP control to target levels. UKPDS, United
Kingdom Prospective Diabetes Study (23); ABCD, Appropriate Blood Pressure Control in Diabetes (27); MDRD,
Modiﬁcation of Diet in Renal Disease study (28); HOT, Hypertension Optimal Treatment study (24); AASK, African
American Study of Kidney Disease and Hypertension (29); IDNT, Irbesartan Diabetic Nephropathy Trial (26); VALUE,
Valsartan Antihypertensive Long-term use Evaluation Trial (25); BP, blood pressure; DBP, diastolic blood pressure; MAP,
mean arterial pressure; SBP, systolic blood pressure
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vided by Kuschnir et al. (43), who showed that the
combination of low-dose nifedipine gastrointestinal
therapeutic system (GITS) with losartan was associ-
ated with improved BP control (greater and more
consistent) than either monotherapy (p < 0.05) in
patients with mild-to-moderate hypertension. Simi-
larly, in hypertensive patients in the Nifedipine and
Candesartan Combination (NICE-Combi) study,
low-dose CCB⁄ARB combination therapy with nifed-
ipine controlled-release (CR) and candesartan was
shown to be more effective than up-titrated cande-
sartan monotherapy for both BP control and renal
protection, with signiﬁcant reductions in urinary mi-
croalbumin excretion levels with combination ther-
apy compared with either monotherapy (p < 0.05)
(38). The Japanese Adalat CR and Valsartan Cost-
Effectiveness Combination (ADVANCE-Combi)
study was conducted to extend the ﬁndings of the
NICE-Combi study and determine the optimal CCB
(nifedipine CR vs. amlodipine) for combination ther-
apy with valsartan in patients with essential hyper-
tension. BP was signiﬁcantly reduced in both
treatment arms, but to a greater extent in patients
receiving nifedipine CR and valsartan than in those
receiving amlodipine and valsartan (p < 0.01) (44).
In the Systolic Evaluation of Lotrel Efﬁcacy and
Comparative Therapies study, CCB and ACE inhibi-
tor combination therapy with amlodipine and bena-
zepril was signiﬁcantly more effective in reducing SBP
and pulse pressure in patients with severe systolic
hypertension than either monotherapy (p < 0.0001)
(45). Signiﬁcantly greater percentages of patients in
the combination group achieved reductions in BP to
guideline-recommended targets compared with either
monotherapy (p < 0.0001) (17). These ﬁndings are
supported by those of a similar study that investi-
gated a CCB and ACE inhibitor combination in
patients with hypertension who were inadequately
controlled on monotherapy. The combination of
manidipine and delapril was shown to be more effec-
tive in reducing BP than either drug alone. At the
end of the treatment period, 73% of patients achieved
controlled BP (46). Efﬁcacy and safety data from the
key studies comparing CCB combination therapy to
monotherapy are presented in Table 2 (38,42,43).
Table 1 The high use of combination therapy in major monotherapy trials
Study
Duration
(years)
Number of
patients Main drug Comparator drugs Patients receiving combination therapy (%)
ACTION (34) 4.9 7665 Nifedipine Placebo 80% beta-blocker; 20% ACE inhibitor; 2% ARB;
12% diuretic; 3% other
ALLHAT (13) 4.9 33,357 Amlodipine Lisinopril; chlorthalidone;
doxazocin
71% of the amlodipine group; 80% of the lisinopril group
68% of the chlorthalidone group
CAMELOT (32) 2 1997 Amlodipine Enalapril; placebo 31% diuretic; 76% beta-blocker; 9% ACE inhibitor;
8% CCB; 2% ARB
EUROPA (31) 4.2 12,218 Perindopril Placebo 62% beta-blocker; 32% CCB; 9% diuretic
HOPE (16) 5 9297 Ramipril Placebo 47% CCB; 40% beta-blocker; 15% diuretic
HOT (24) 3.8 18,790 Felodipine No comparator 41% ACE inhibitor; 28% beta-blocker 22% diuretic
IDNT (26) 2.6 (mean
follow-up)
1715 Irbesartan Amlodipine; placebo Both treatment arms received on average 3 non-study
drugs*
INVEST (33) 2.7 (mean
follow-up)
22,576 Verapamil Atenolol trandolapril;
HCTZ
67% of the verapamil group and 69% of the
atenolol group received 2 or 3 strategy drugs
LIFE (14) 4 9193 Losartan Atenolol 66% of the losartan group; 62% atenolol group
RENAAL (30) 3.4 1513 Losartan Placebo 77.9% CCB (60.7% DHP CCB); 83.8% diuretic; 40.2%
alpha-blockers; 34.1% beta-blockers; 18% centrally acting
agents
Syst-Eur (35) 2.0 4695 Nitrendipine Placebo enalapril;
HCTZ
38% enalapril; 18% HCTZ
Syst-China (39) 3 1253 Nitrendipine Placebo 19% captopril; 3% HCTZ; 3% other
VALUE (25) 4.2 15,245 Valsartan Amlodipine In the valsartan vs. amlodipine groups: 21 vs. 19% ACE inhibitor;
24 vs. 18% a-blocker; 48 vs. 43% beta-blockers; 13 vs.
15% diuretics; 4 vs. 4% diuretic combinations
*Non-study drugs to control BP included diuretics, beta-blockers, peripheral alpha blockers and central a2 antagonists. Add-on therapy administered to achieve
BP goals. Add-on therapy to nitrendipine. ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blockers; CCB, calcium channel blocker; HCTZ,
hydrochlorothiazide.
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Data from outcome trials show that CCB therapy
plus additional add-on treatment not only lowers BP
but also improves patient outcomes. The Hyperten-
sion Optimal Treatment trial showed that intensive
lowering of BP with CCB-based therapy (felodipine
as baseline therapy with the addition of other antihy-
pertensive agents according to a ﬁve-step regimen)
was associated with a low rate of CV events (22). In
the Systolic Hypertension in Europe (Syst-Eur) and
China (Syst-China) studies, the dihydropyridine CCB
nitrendipine, with the addition of a diuretic and an
ACE inhibitor (enalapril in Syst-Eur and captopril in
Syst-China) reduced the rate of CV complications in
elderly patients with isolated systolic hypertension
(35,39). The additional beneﬁts of CCB-based ther-
apy in the elderly patients were further supported by
the Shanghai Trial Of Nifedipine in the Elderly, in
which nifedipine GITS reduced the incidence of CV
events, including stroke, in elderly individuals with
hypertension (47).
Data from ASCOT showed that CCB-based treat-
ment is more effective than a beta-blocker-based reg-
imen for reducing mortality and CV events (20).
ASCOT compared the combination of the CCB am-
lodipine plus the ACE inhibitor perindopril (added
as required) with the beta-blocker atenolol plus the
diuretic bendroﬂumethiazide (added as required) in
a group of patients with hypertension and at least
three other CV risk factors (20). Treatment with a
CCB-based therapy reduced the risks of non-fatal
myocardial infarction or fatal CHD (p = 0.046), fatal
and non-fatal stroke (p = 0.0003), total CV events
and procedures (p < 0.0001), all-cause mortality
(p = 0.025) and diabetes (p < 0.0001) compared
with the beta-blocker-based therapy (20). Thus, the
CCB-based regimen prevented more major CV
events and was associated with a reduced incidence
of diabetes compared with the diuretic-based regi-
men. The results of ASCOT therefore support the
beneﬁts of combined antihypertensive therapy for
lowering BP and signiﬁcantly reducing the risk of
CV events.
Additional studies
In addition, there are several ongoing studies to
determine the optimal antihypertensive combination
therapy with the most favourable safety proﬁle for
lowering BP and protecting against CV events. The
Combination Therapy of Hypertension to Prevent
Cardiovascular Events study is a multicentre trial
assessing CV outcomes in hypertensive patients trea-
ted with various drug combinations including ARBs,
beta-blockers or diuretics in combination with a
CCB (benidipine) (48). The Avoiding Cardiovascu-
lar Events Through Combination Therapy in
Patients Living with Systolic Hypertension trial is
the ﬁrst randomised controlled trial to compare the
effects of ACE inhibitor⁄diuretic and ACE inhibi-
tor⁄CCB ﬁrst-line combination therapies (benazep-
ril⁄hydrochlorothiazide vs. benazepril⁄amlodipine)
in hypertensive patients with additional CV risk fac-
tors, including renal disease and diabetes (49).
Results from these trials should provide new
Table 2 Comparison of efﬁcacy and safety of CCB combination therapy vs. monotherapy in clinical trials
Study Efﬁcacy Safety
NICE-Combi: nifedipine and candesartan low-dose
combination therapy vs. candesartan monotherapy
in patients with essential hypertension (38)
BP reduction signiﬁcantly greater in combination
arm (SBP 12.1 mmHg, DBP 8.7 mmHg) vs.
monotherapy arm (SBP 4.1 mmHg,
DBP 4.6 mmHg)
Decreased urinary microalbumin excretion in
combination arm (p < 0.05) but not monotherapy
arm
High-dose monotherapy vs. low-dose combination
therapy of CCBs and ARBs (42)
In patients whose hypertension not controlled with
monotherapy, low-dose combination therapy
achieved BP control in 61.6%, vs. 42.8% with
high-dose CCBs and 40.5% with ARBs
Combination therapy exhibited better
trough-to-peak variability, hypertensive burden
and BP variability
Low-dose combination therapy better tolerated
than high-dose CCB monotherapy
Low-dose nifedipine GITS and losartan in patients
with mild-to-moderate hypertension (43)
DBP lower in patients receiving combination
treatment vs. losartan alone
DBP trough-to-peak ratio and smoothness index
highest in combination group (70%)
Adverse events similar between treatment groups
ARB, angiotensin-receptor blockers; BP, blood pressure; CCB, calcium channel blocker; DBP, diastolic blood pressure; GITS, gastrointestinal therapeutic system;
NICE-Combi, Nifedipine and Candesartan Combination; SBP, systolic blood pressure.
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hypertensive patients.
Several other large, randomised clinical studies
have investigated the use of antihypertensive combi-
nation therapies in high-risk patient populations,
including those with impaired renal function, diabe-
tes or CAD, in whom BP is more difﬁcult to control
to target levels. These will be discussed in more detail
in the following sections.
Patients at risk of stroke
There is strong evidence to show that hypertension is
probably the most important risk factor for stroke
(50) – the risk of stroke increases linearly with increas-
ing BP (51). In patients at risk of stroke, reducing BP
has a signiﬁcant beneﬁt: a 5–6 mmHg reduction in BP
has been shown to reduce the risk of stroke by 38%
(52). The CCB-based antihypertensive strategies in
particular have been shown to provide speciﬁc beneﬁts
in patients at risk of stroke (47). The combination of a
CCB and an ACE inhibitor has been shown to signiﬁ-
cantly reduce the risk of stroke in elderly patients with
isolated systolic hypertension, with relative risk reduc-
tions vs. placebo of 38% (p = 0.01) and 42%
(p = 0.003) in Syst-Eur and Syst-China respectively
(35,39). More recently, ASCOT demonstrated a
greater reduction in the risk of non-fatal or fatal stroke
with CCB plus additional ACE inhibitor therapy com-
pared with a beta-blocker plus additional diuretic
therapy (p = 0.0003) (20). In A Coronary Disease
Trial Investigating Outcome with Nifedipine GITS
(ACTION), the addition of the CCB nifedipine GITS
to best practice therapy for CAD, including other anti-
hypertensive agents, reduced the risk of debilitating
stroke by 33% in hypertensive patients (p = 0.029)
compared with hypertensive patients who did not
receive additional CCB therapy (49).
Beneﬁts of CCB-based therapy
in high-risk patient populations
The safety and efﬁcacy of CCBs have also been dem-
onstrated in several high-risk patient populations,
such as those with impaired renal function, diabetes
or CAD.
CCB combination therapy and renal function
In hypertensive patients at high CV risk, renal dys-
function has been shown to be an important predic-
tor of CV risk and to act as a prognostic marker of
progression to CVD (53). Furthermore, BP is more
difﬁcult to control in patients with impaired renal
function, particularly in those with comorbid diabe-
tes. Importantly, tight BP control has been shown to
slow the progression of renal failure (54).
ACTION examined the beneﬁts of additional
nifedipine GITS intervention in patients with stable
angina and CAD who were receiving best practice
therapy. Almost 40% of the patients in ACTION
had evidence of renal dysfunction (34,55), and the
results showed that, when administered in addition
to best practice therapy for CAD, nifedipine GITS
signiﬁcantly reduced BP (p < 0.0001 compared
with placebo) even in patients with renal dysfunc-
tion in whom it is more difﬁcult to achieve BP
control.
In the International Nifedipine GITS Study: Inter-
vention as a Goal in Hypertension Treatment
(INSIGHT), patients with mild-to-moderate hyper-
tension received nifedipine GITS or the diuretic
combination co-amilozide, with the addition of ate-
nolol (or enalapril if atenolol was contraindicated)
followed by addition of any other antihypertensive
drug (other than CCBs or diuretics) if BP targets
were not achieved. The study showed that, in hyper-
tensive patients at high CV risk, renal function was
better preserved with nifedipine GITS than with
diuretics (p < 0.0001). The improved renal function
with nifedipine GITS was indicated by better pre-
served creatinine clearance, which is a marker of
renal function, and fewer patients treated with nifed-
ipine GITS had progressive renal deterioration com-
pared with those treated with co-amilozide (34,53).
Further evidence of the beneﬁts of CCBs in
patients with impaired renal function was provided
by the Antihypertensive and Lipid-lowering Treat-
ment to Prevent Heart Attack Trial, which included
a post hoc analysis of the changes in estimated glo-
merular ﬁltration rate with a CCB (amlodipine), a
diuretic (chlorthalidone) and an ACE inhibitor (lis-
inopril). In this trial, the incidence of end-stage renal
disease was similar for all three treatment arms, but
estimated creatinine clearance was signiﬁcantly better
preserved with amlodipine than with chlorthalidone
or lisinopril (13). Taken together, the results of these
studies demonstrate that dihydropyridine CCBs con-
fer prognostic beneﬁts in terms of renal function.
CCB combination therapy and diabetes
Individuals with hypertension have a ‡ 2-fold
increased risk of developing diabetes (56). In addi-
tion, hypertension is twice as common in patients
with diabetes compared with those without diabetes;
it accounts for up to 75% of CV risk in this patient
population, leading to substantial increases in mor-
bidity and mortality (57).
Hypertension acts synergistically with diabetes in
increasing the risks of macro- and microvascular dia-
betic complications (58,59). In patients with type 1
diabetes mellitus, hypertension is often the result of
786 Combination therapy for effective hypertension management
ª 2008 The Author
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, May 2008, 62, 5, 781–790underlying nephropathy; whereas in those with type
2 diabetes mellitus, hypertension may be present as
part of the metabolic syndrome (60).
Owing to the increased CV risk associated with
diabetes, target BP is lower in patients with diabetes
(130⁄80 mmHg) than in patients with primary
hypertension (5,6). However, fewer than one-third of
individuals with diabetes achieve BP targets, in part
because of the inherent difﬁculty of controlling BP
in these patients (59). Current guidelines recognise
the importance of achieving target BP levels and rec-
ommend that all patients with diabetes and hyper-
tension should be treated with a combination of
several antihypertensive drugs (one of which should
be an ARB or ACE inhibitor) (6,61).
Several studies have shown that CCB-based combi-
nation therapy can improve clinical outcomes in
individuals with diabetes. In INSIGHT, nifedipine
GITS reduced the risk of all-cause mortality in
patients with diabetes compared with those without
diabetes and reduced the frequency of new cases of
diabetes compared with diuretic therapy (62). Fur-
ther support for CCB-based combination therapy in
patients with diabetes is provided by ACTION, the
results of which showed that nifedipine GITS, in
addition to best practice therapy for CAD, signiﬁ-
cantly reduced BP and the risk of CV events (34).
The Reduction of Endpoint in NIDDM with the
Angiotensin II receptor Antagonist Losartan study
investigated the addition of losartan to current
hypertensive medication in patients with diabetes
and diabetic nephropathy. Most patients were taking
dihydropyridine CCBs, and the addition of losartan
led to signiﬁcant renal-protective effects, with a risk
reduction of 28% in end-stage renal disease
(p = 0.002). This beneﬁt was beyond that attribut-
able to the BP-lowering effect alone (30,51).
CCB combination therapy and CAD
In ACTION, more than 50% of patients had inade-
quately controlled BP at baseline, despite receiving
best practice therapy at study entry (34). At baseline,
20% of patients were receiving ACE inhibitors;
‡ 10% were receiving diuretics; 2% were receiving
ARBs and ‡ 80% were receiving beta-blockers. The
addition of nifedipine GITS to best practice CAD
therapy provided further beneﬁt by increasing the
proportion of patients who achieved BP targets: the
percentage of patients with BP above target was
reduced from 52% at baseline to 35% in the nifedi-
pine GITS group and 47% in the placebo group. The
effects of nifedipine GITS on BP lowering resulted in
improved patient outcomes, which were mainly
attributable to reductions in stroke or transient
ischaemic attack and the need for coronary angiogra-
phy or coronary interventions (34). The beneﬁts of
nifedipine GITS intervention were also evident in
those patients with additional complications, includ-
ing patients with underlying atrial ﬁbrillation (63).
Further analysis of the ACTION results revealed
even greater beneﬁts in the subgroup of patients with
inadequate BP control at baseline (64). There was a
signiﬁcant 13% reduction (p < 0.05) in the com-
bined incidence of all-cause mortality, myocardial
infarction, refractory angina, heart failure, debilitat-
ing stroke and peripheral revascularisation in patients
receiving nifedipine GITS in addition to best practice
therapy. In addition, a 38% reduction in new overt
heart failure and a 33% reduction in the incidence of
debilitating stroke were observed in patients treated
with nifedipine GITS. Together, these data clearly
indicate that long-acting CCBs are an effective and
well-tolerated combination therapy choice in high-
risk patients with CAD.
Beneﬁts of antihypertensive drug
combinations with complementary
modes of action
Hypertension is a multifactorial disease, so disrup-
tion of a single physiological pathway is often insufﬁ-
cient to control BP. Therefore, a combination of two
drugs with different but complementary modes of
action is often needed to achieve effective BP control.
This is supported by hypertension guidelines, which
highlight the need for drugs to be combined effec-
tively and emphasise the beneﬁts of drugs with dif-
ferent mechanisms of action on a multi-regulated
variable such as BP (2,6,7).
Dihydropyridine CCBs and inhibitors of the RAAS
pathway (namely, ACE inhibitors and ARBs) are
widely used in patients with CVD. They have com-
plementary mechanisms of action so, when used in
combination, have synergistic effects on pathological
changes in the vasculature and end organs, providing
beneﬁts in addition to BP control.
Calcium channel blockers primarily affect the cel-
lular interactions of endothelial cells, smooth muscle
cells, monocytes and thrombocytes, which have key
roles in the early phases of atherosclerosis develop-
ment. There is also evidence to show that CCBs
affect the nitric oxide system in endothelial cells. Sev-
eral studies have shown that endothelium-dependent
relaxation, which is impaired in individuals with
hypertension, can be restored by treatment with
dihydropyridine CCBs (65–67). CCBs also have
vascular-protective effects, which are evident during
the later stages of atherosclerosis. The International
Nifedipine Trial on Anti-atherosclerotic Therapy
study demonstrated a 28% reduction in new
Combination therapy for effective hypertension management 787
ª 2008 The Author
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, May 2008, 62, 5, 781–790atherosclerotic lesions in patients with mild CAD
with nifedipine GITS (68). In patients with signiﬁ-
cant atherosclerosis, even greater reductions in
lesions are observed with a CCB and statin combina-
tion, as shown in the Regression Growth Evaluation
Statin Study (69). CCBs have also been shown to
have beneﬁcial effects on early carotid wall changes
by reducing intima-media thickness (70–72), and can
improve coronary endothelial function in patients
with CAD (73). By contrast, ARBs and ACE inhibi-
tors act on the RAAS hormone pathway to block sig-
nalling and promote relaxation of blood vessels,
thereby controlling BP and providing beneﬁcial
effects on CV morbidity and mortality in high-risk
patients and preserving renal function. In addition, it
was recently shown that ARBs have a speciﬁc anti-
inﬂammatory effect by reducing levels of inﬂam-
matory markers such as tumour necrosis factor-a,
interleukin-6 and C-reactive protein (74). In addition
to effective BP lowering, combination therapy with a
CCB and an ARB would be expected to provide
additional beneﬁts through effects on both oxidative
stress and microinﬂammation.
Conclusions
Both guideline recommendations and clinical trial
evidence support the use of combination therapy in
managing hypertension, particularly in patients at
increased risk of CV events and those for whom BP
targets are lower because of the need for intensive
management of additional risk factors, such as those
with CAD, metabolic syndrome, diabetes or renal
dysfunction. In a large proportion of patients, it is
difﬁcult to lower BP to target levels using antihyper-
tensive monotherapy, so more intensive intervention,
speciﬁcally combination antihypertensive therapy, is
often required. Clinical studies have proved the efﬁ-
cacy of CCB-based combination strategies in a wide
range of high-risk patient groups.
Combination therapy with antihypertensive agents
that have different but complementary mechanisms
of action not only avoids unnecessary drug interac-
tions and adverse events, but also maximises the ben-
eﬁts of agents that have additional effects beyond BP
lowering. For example, there is evidence to show that
the combination of CCBs and ARBs provides end-
organ protection through synergistic mechanisms.
CCBs are effective with all other antihypertensive
agents, and this ﬂexibility makes them ideal as part
of a ﬁrst-line combination strategy to achieve target
BP and provide additional CV beneﬁts, without
compromising safety in patients at increased CV risk.
In clinical practice, there is still much inconsis-
tency with regards to stepwise treatment of patients
and the decision to increase drug dose, switch ther-
apy or add another drug. Combination therapy may
still be considered a last resort in the treatment of
hypertension and be rarely used as initial or ﬁrst-line
therapy. The treatment paradigm is now changing
and more patients are being treated in line with
guideline recommendations, which focus on overall
CV risk and therefore recommend multiple-drug
strategies early in the course of treatment.
Ongoing studies will provide further data to sup-
port the beneﬁts of antihypertensive combination
therapy on clinical outcomes when used as a ﬁrst-
line strategy. Increased efforts to use combination
therapy much earlier in the course of treatment and
increased adherence to global guidelines will ensure
patients achieve and sustain BP control in addition
to reducing the risk of CV events.
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